Replimune
Woburn, United States · Biotechnology, Health Care
Replimune is working to advance the science of oncolytic immunotherapy to improve on existing therapies and help treat more patients with a variety of tumor types. Oncolytic immunotherapy uses viruses that have been modified to selectively replicate in and kill tumors. Replimunes' goal is to develop powerful therapies to overcome cancer.
Key facts
- Headquarters
- Woburn, United States
- Employees
- Unknown
- Industries
- Biotechnology, Health Care
- Status
- Public (REPL)
- Website
- replimune.com
- Company page
Recent activity at Replimune
- : Replimune Group Appoints Michelle DiNapoli as Chief Commercial Officer
- : Replimune Appoints Michelle DiNapoli as Chief Commercial Officer
- : Replimune Group, Inc. advances cancer treatment with the submission of RP1 Biologics License Application and receives Breakthrough Therapy designation.
- : Replimune Group, Inc. Grants Inducement Equity Awards to Newly Hired Non-Executive Employees
- : Sushil Patel Succeeds Philip Astley-Sparke as CEO of Replimune Group, Inc.
- : Replimune Secures $200 Million In Non-Dilutive Debt Financing From Hercules Capital, Inc.
Replimune funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2022 | Debt Financing | $200.0M |
Leadership
- Michelle DiNapoli, Chief Commercial Officer
- Michelle DiNapoli, Chief Commercial Officer
- Sushil Patel, Ph.D., Chief Commercial Officer
- Emily Hill
- Philip Astley-Sparke, Chief Executive Officer
- Tanya Lewis, Chief Development Operations Officer
Verified email and direct lines for Replimune’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Replimune files 1 employee benefit plan with the U.S. Department of Labor. The next plan year renews in Dec 2026.
Replimune in the news
- After Wild Ride, FDA Grants Accelerated Approval for Replimune’s RP1 Plus Nivolumab in Advanced Melanoma - The American Journal of Managed Care (Aug 06, 2026)
- FDA Grants Accelerated Approval to Replimune's Tudriqev Plus Nivolumab for Advanced Melanoma - BioPharm International (Aug 07, 2026)
- US FDA approves Replimune's skin cancer drug after prior rejections - Reuters (Aug 06, 2026)
- FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma - OncLive (Jul 29, 2026)
- FDA expert committee votes in favor of Replimune’s melanoma treatment - STAT (Jul 30, 2026)
- FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study - Pharmaceutical Executive (Jul 31, 2026)
- FDA Approves RP1 Plus Nivolumab for Advanced Melanoma - Dermatology Times (Aug 07, 2026)
- Opinion | The FDA, Replimune and a New Flu Shot - WSJ (Aug 02, 2026)
Companies similar to Replimune
- Scarlet · Biotechnology, Health Care
- Concentra Group Holdings Parent · Biotechnology, Health Care
- ZoeNCure Therapeutics Pvt. Ltd · Biotechnology, Health Care
- Capitan Orthopedics · Biotechnology, Health Care
- Abcuro · Biotechnology, Health Care
About Replimune: questions and answers
What does Replimune do?
Replimune is working to advance the science of oncolytic immunotherapy to improve on existing therapies and help treat more patients with a variety of tumor types. Oncolytic immunotherapy uses viruses that have been modified to selectively replicate in and kill tumors. Replimunes' goal is to develop powerful therapies to overcome cancer.
Where is Replimune headquartered?
Replimune is headquartered in Woburn, United States.
Has Replimune raised funding?
Yes. Fundz has recorded 1 funding event for Replimune. The most recent, Debt Financing of $200.0M, was in Oct 2022.
Who leads Replimune?
Philip Astley-Sparke is a Chief Executive Officer at Replimune.
What is the latest news on Replimune?
On Aug 23, 2026, Replimune Group Appoints Michelle DiNapoli as Chief Commercial Officer
Is Replimune a public company?
Yes. Replimune is publicly traded under the ticker REPL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy